ZEJULA (niraparib)
Zejula (niraparib) is an oral PARP inhibitor that blocks DNA repair in cancer cells, used as maintenance therapy for advanced or recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.
Where this therapy is approved with a companion diagnostic
Each row represents a defined combination of indication, biomarker criteria, and ZEJULA. Select a testing pathway to see the eligible companion diagnostic tests.
Approvals where ZEJULA is tied to a specific indication and biomarker definition.
| Indication | Biomarker criteria | Notes | |
|---|---|---|---|
Ovarian Cancer Solid Tumor · Ovary | HRD
| View testing pathway → |
Approvals defined at the solid tumor level where biomarker criteria determine eligibility for ZEJULA.
No tumor-agnostic companion diagnostic approvals are currently mapped for this therapy.
Tests used in these approvals
These assays are identified in FDA labeling or sponsor materials as companion diagnostics or acceptable tests when considering ZEJULA for eligible patients.